Podoplanin-mediated cell adhesion through extracellular matrix in oral squamous cell carcinoma

Laboratory Investigation

Volumn 93, Issue 8, 2013, Pages 921-932

  Tsuneki, Masayuki ^a   Yamazaki, Manabu ^a   Maruyama, Satoshi ^b   Cheng, Jun ^a   Saku, Takashi ^a,b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

CD44; Cell adhesion; Extracellular matrix; Hyaluronan; Oral squamous cell carcinoma; Podoplanin

Indexed keywords

BETA ACTIN; EZRIN; HERMES ANTIGEN; HYALURONIC ACID; PODOPLANIN; SMALL INTERFERING RNA;

ADULT; ARTICLE; CARCINOMA CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL FEATURE; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION PROFILING; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84881079146     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.86     Document Type: Article

References (42)

1. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43- kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997;151: 1141-1152.
2. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 2005;46: 396-402.
3. Mohammed RA, Ellis IO, Lee AH, et al. Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms. Histopathology 2009;55: 1-9.
4. Kundu S, Cheng J, Maruyama S, et al. Lymphatic involvement in the histopathogenesis of mucous retention cyst. Pathol Res Pract 2007;203: 89-97.
5. Tateyama H, Sugiura H, Yamatani C, et al. Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome. Hum Pathol 2011;42: 533-540.
6. Ariizumi T, Ogose A, Kawashima H, et al. Expression of podoplanin in human bone and bone tumors: new marker of osteogenic and chondrogenic bone tumors. Pathol Int 2010;60: 193-202.
7. Tsuneki M, Maruyama S, Yamazaki M, et al. Podoplanin expression profiles characteristic of odontogenic tumor-specific tissue architectures. Pathol Res Pract 2012;208: 140-146.
8. Minardi D, D'anzeo G, Lucarini G, et al. D2-40 immunoreactivity in penile squamous cell carcinoma: a marker of aggressiveness. Hum Pathol 2011;42: 1596-1602.
9. Suzuki H, Onimaru M, Koga T, et al. High podoplanin expression in cancer cells predicts lower incidence of nodal metastasis in patients with lung squamous cell carcinoma. Pathol Res Pract 2011;207: 111-115.
10. Yuan P, Temam S, El-Naggar A, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006;107: 563-569.
11. Kreppel M, Scheer M, Drebber U, et al. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch 2010;456: 473-482.
12. Kawaguchi H, El-Naggar A, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008;26: 354-360.
13. Funayama A, Cheng J, Maruyama S, et al. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiology 2011;78: 171-180.
14. Ikarashi T, Ida-Yonemochi H, Ohshiro K, et al. Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 2004;33: 87-95.
15. Ahsan MS, Yamazaki M, Maruyama S, et al. Differential expression of perlecan receptors, a-dystroglycan and integrin b1, before and after invasion of oral squamous cell carcinoma. J Oral Pathol Med 2011;40: 552-559.
16. Tilakaratne WM, Kobayashi T, Ida-Yonemochi H, et al. Matrix metalloproteinase 7 and perlecan in oral epithelial dysplasia and carcinoma in situ: an aid for histopathologic recognition of their cell proliferation centers. J Oral Pathol Med 2009;38: 348-355.
17. Martin-Villar E, Megias D, Castel S, et al. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006;119: 4541-4553.
18. Martin-Villar E, Fernandez-Munoz B, Parsons M, et al. Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell 2010;21: 4387-4399.
19. Tsuneki M, Maruyama S, Yamazaki M, et al. Extracellular heat shock protein A9 is a novel interaction partner of podoplanin in oral squamous cell carcinoma cells. Biochem Biophys Res Commun 2013;434: 124-130.
20. Wicki A, Lehembre F, Wick N, et al. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006;9: 261-272.
21. Metwaly H, Maruyama S, Yamazaki M, et al. Parenchymal-stromal switching for extracellular matrix production on invasion of oral squamous cell carcinoma. Hum Pathol 2012;43: 1973-1981.
22. Maruyama S, Cheng J, Yamazaki M, et al. Metastasis-associated genes in salivary adenoid cystic carcinoma and oral squamous cell carcinoma: a differential DNA chip analysis between metastatic and non-metastatic cell systems. Cancer Genet Cytogenet 2010;196: 14-22.
23. Cheng J, Irié T, Munakata R, et al. Biosynthesis of basement membrane molecules by salivary adenoid cystic carcinoma cells: an immunofluorescence and confocal microscopic study. Virchows Arch 1995;426: 577-586.
24. Tsuneki M, Yamazaki M, Cheng J, et al. Combined immunohistochemistry for the differential diagnosis of cystic jaw lesions: its practical use in surgical pathology. Histopathology 2010;57: 806-813.
25. Koh SS, Wei JP, Li X, et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod Pathol 2012;25: 828-837.
26. Zhu K, Fukasawa I, Furuno M, et al. Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol 2005;97: 405-409.
27. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999;144: 789-801.
28. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007;2: 329-333.
29. Culty M, Miyake K, Kincade PW, et al. The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol 1990;111: 2765-2774.
30. Luo X, Ruhland MK, Pazolli E, et al. Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway. Mol Cancer Res 2011;9: 1018-1029.
31. Jijiwa M, Demir H, Gupta S, et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 2011;6: e24217.
32. Chetty C, Vanamala SK, Gondi CS, et al. MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cell Signal 2012;24: 549-559.
33. Ladeda V, Aguirre Ghiso JA, Bal de Kier Joffe E. Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells. Exp Cell Res 1998;242: 515-527.
34. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166: 913-921.
35. Cueni LN, Hegyi I, Shin JW, et al. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol 2010;177: 1004-1016.
36. Ogasawara S, Kato-Kaneko M, Price JE, et al. Characterization of antipodoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma 2008;27: 259-267.
37. Mythreye K, Blobe GC. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal 2009;21: 1548-1558.
38. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002;277: 4589-4592.
39. Brown TA, Bouchard T, John TS, et al. Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 1991;113: 207-221.
40. Tsukita S, Yonemura S, Tsukita S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol 1997;9: 70-75.
41. Tang F, Wang D, Duan C, et al. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting rho kinasemediated ezrin phosphorylation at threonine 567. J Biol Chem 2009;284: 27456-27466.
42. Suzuki H, Onimaru M, Yonemitsu Y, et al. Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells. Mol Cancer 2010;9: 287.